Immunology · Mendelian Susceptibility to Mycobacterial Diseases Due to Complete RORC Deficiency

Treatment and Long-Term Management Strategies

At a Glance

Children with complete RORC deficiency may need months to years of combination antimycobacterial treatment, tailored immune support, and regular liver, kidney, vision, and hearing checks. A stem cell transplant is a high-risk option reserved for severe, persistent disease and requires expert assessment.

Treating complete RORC deficiency requires a specialized, two-front approach: clearing active infections and building a long-term defense strategy. Because this condition is ultra-rare, there is no single “one-size-fits-all” protocol. Your child’s care will be led by a team of immunologists and infectious disease specialists who will tailor treatment to your child’s specific needs ^[1]^[2].

Important: Never self-start, stop, or adjust your child’s antimicrobial medications without explicit instructions from the treating team.

Managing Mycobacterial Infections (BCG-osis)

If your child has developed a severe reaction to the BCG vaccine or another mycobacterial infection, the priority is aggressive, long-term medication. This is not a standard 10-day course of antibiotics; treatment often lasts for many months (sometimes 12 to 24 months or longer), individualized by the specialist team, to ensure the bacteria are completely cleared from the body ^[3]^[4].

Combination Therapy: Doctors typically use a regimen of three or more medications. Common choices include rifampin, isoniazid, and ethambutol ^[5]^[6]. In severe or widespread (disseminated) cases, they may add specialized antibiotics like clarithromycin (a macrolide) or ciprofloxacin (a fluoroquinolone) ^[5].
The Pyrazinamide Exception: Most tuberculosis treatments include a drug called pyrazinamide. However, if the infection is confirmed to be the bacteria in the BCG vaccine (M. bovis), it is naturally resistant to it. Your doctor will likely exclude this drug to avoid unnecessary side effects ^[7]^[8].
Susceptibility Testing: Your team will try to grow the bacteria in a lab to see exactly which drugs kill them best. This allows them to “fine-tune” the treatment for your child ^[7].

Supporting the Immune System

Because your child’s body struggles to produce its own “alarm signals,” doctors may use targeted therapies to help the immune system recognize and fight germs.

Recombinant Interferon-gamma (IFN- $\gamma$ ): This is a laboratory-made version of the signaling protein whose production is impaired in your child ^[9]. Because children with RORC deficiency can usually respond to the signal even if they can’t make it, injecting this medication as an expert-selected adjunct may help “boost” their immune cells to kill bacteria. Evidence for recombinant IFN- $\gamma$ in this specific disorder is limited and response is variable ^[2]^[10].
Antifungal Therapy: To manage chronic mucocutaneous candidiasis (CMC), your child may need ongoing antifungal medications (such as fluconazole) to keep oral thrush and skin yeast infections under control ^[11]^[12].
Prophylaxis: Once an active infection is cleared, your doctor might keep your child on secondary prophylaxis (preventative antimicrobials) to prevent the infection from returning ^[13]^[14]. This need, drug choice, and duration are individualized.

Monitoring for Safety

Long-term use of powerful antibiotics requires “safety checks” to protect your child’s organs.

Liver and Kidneys: Medications like isoniazid and rifampin can sometimes stress the liver. Your child will need regular blood tests to check liver enzymes (AST/ALT) and kidney function (creatinine) ^[15]^[16].
Vision and Hearing: Some mycobacterial drugs can rarely affect a child’s sight or hearing. Kidney and hearing toxicity are especially relevant when aminoglycosides are used. Your team may recommend baseline and follow-up exams with a specialist ^[17]. Report any vision or hearing changes, jaundice, dark urine, or severe vomiting promptly.

Advanced Option: Hematopoietic Stem Cell Transplantation (HSCT)

For some children, medications alone may not be enough to provide a long-term cure. In these cases, a stem cell transplant may be considered by an experienced primary immunodeficiency center ^[2].

The Goal: HSCT replaces your child’s immune system with healthy cells from a donor. If successful, these new cells will have a working RORC gene and can produce the necessary IFN- $\gamma$ and IL-17 signals ^[18].
The Risk: This is a high-intensity procedure with significant risks, including graft-versus-host disease (GvHD) and severe infections during the recovery period. Evidence and indications for HSCT in complete RORC deficiency are limited and highly case-specific; it is not a routine next step. It is usually reserved for children with severe, persistent disease that does not respond to other treatments ^[6]^[18].

Important: The BCG vaccine and other live vaccines remain strictly contraindicated (not allowed) for your child, as they can trigger a new, life-threatening infection ^[19].

Common questions in this guide

How long is treatment for a BCG infection in complete RORC deficiency?

Treatment usually combines three or more antimycobacterial medicines and often lasts 12 to 24 months or longer. The exact duration depends on how widely the infection has spread, susceptibility results, and the child’s response, so the specialist team must set the plan.

Why is pyrazinamide usually left out of BCG infection treatment?

BCG comes from M. bovis, which is naturally resistant to pyrazinamide. Clinicians commonly exclude pyrazinamide from a BCG regimen to avoid an ineffective drug and unnecessary side effects, but the treating team should confirm the final combination.

Can interferon-gamma help a child with complete RORC deficiency?

Recombinant interferon-gamma may be considered as an expert-selected add-on because some children can respond to the signal even though their bodies do not make enough of it. Evidence in complete RORC deficiency is limited, and responses vary, so it should not be started without specialist guidance.

What monitoring is needed during long-term antimycobacterial treatment?

Regular blood tests may check liver enzymes and kidney function, and baseline and follow-up vision or hearing exams may be needed depending on the medicines used. Report vision or hearing changes, yellowing of the eyes, dark urine, or severe vomiting promptly to the medical team.

Are BCG and other live vaccines safe in complete RORC deficiency?

No. BCG and other live vaccines are contraindicated because they can cause a new, potentially life-threatening infection in a child with complete RORC deficiency. Families should review every vaccine with the treating immunology team.

When might a stem cell transplant be considered for complete RORC deficiency?

Hematopoietic stem cell transplantation may be discussed at an experienced primary immunodeficiency center when severe disease persists despite medical treatment. It is not routine and carries major risks, including graft-versus-host disease and severe infections during recovery, so the decision is highly individualized.

Will my child need preventive antimicrobials after the infection clears?

The specialist team may prescribe secondary prophylaxis after an active infection is cleared to reduce the chance of recurrence. The drug, need, and duration depend on the child’s infection history, immune status, and response to treatment.

Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Mendelian susceptibility to mycobacterial disease: 2014-2018 update.
Rosain J, Kong XF, Martinez-Barricarte R, et al.
Immunology and cell biology 2019; (97(4)):360-367 doi:10.1111/imcb.12210.
PMID: 30264912
2
Mendelian susceptibility to mycobacterial diseases: State of the puzzle.
Errami A, Bousfiha AA
Qatar medical journal 2023; (2023(2)):25 doi:10.5339/qmj.2023.sqac.25.
PMID: 38025345
3
A 25-year surveillance of disseminated Bacillus Calmette-Guérin disease treatment in children in Southern Iran.
Amanati A, Pouladfar G, Kadivar MR, et al.
Medicine 2017; (96(52)):e9035 doi:10.1097/MD.0000000000009035.
PMID: 29384896
4
Case report: IL12RB1 deficiency in an infant with disseminated Bacille Calmette-Guérin disease.
Ma X, Chen J, Cheng J, Wang J
Frontiers in immunology 2025; (16()):1728612 doi:10.3389/fimmu.2025.1728612.
PMID: 41668770
5
Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series.
Mahdaviani SA, Fallahi M, Jamee M, et al.
Annals of clinical microbiology and antimicrobials 2022; (21(1)):8 doi:10.1186/s12941-022-00500-y.
PMID: 35232430
6
DISSEMINATED BACILLUS-CALMETTE-GUÉRIN INFECTIONS AND PRIMARY IMMUNODEFICIENCY DISORDERS IN SINGAPORE: A SINGLE CENTER 15-YEAR RETROSPECTIVE REVIEW.
Ong RYL, Chan SB, Chew SJ, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020; (97()):117-125 doi:10.1016/j.ijid.2020.05.117.
PMID: 32497805
7
Development of a Multiplex Real-Time PCR Assay for Mycobacterium bovis BCG and Validation in a Clinical Laboratory.
Duffy SC, Venkatesan M, Chothe S, et al.
Microbiology spectrum 2021; (9(2)):e0109821 doi:10.1128/Spectrum.01098-21.
PMID: 34494864
8
Pediatric Mycobacterium bovis Infection: Clinical Spectrum, BCG-Related Disease, Primary Immunodeficiency, and a Comprehensive Review of the Literature.
Mete Atasever N, Dede E, Köksalan K, et al.
Vaccines 2026; (14(10)) doi:10.3390/vaccines14100867.
PMID: 42931396
9
The application of HPLC/MS analysis with a multi-enzyme digest strategy to characterize different interferon product variants produced from Pichia pastoris.
Wang Y, Liu D, Crowell LE, et al.
Amino acids 2019; (51(9)):1353-1363 doi:10.1007/s00726-019-02772-9.
PMID: 31446487
10
Recombinant IFN-γ1b Treatment in a Patient with Inherited IFN-γ Deficiency.
Rosain J, Kiykim A, Michev A, et al.
Journal of clinical immunology 2024; (44(3)):62 doi:10.1007/s10875-024-01661-5.
PMID: 38363432
11
IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.
Okada S, Markle JG, Deenick EK, et al.
Science (New York, N.Y.) 2015; (349(6248)):606-613 doi:10.1126/science.aaa4282.
PMID: 26160376
12
Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity.
Okada S, Puel A, Casanova JL, Kobayashi M
Clinical & translational immunology 2016; (5(12)):e114 doi:10.1038/cti.2016.71.
PMID: 28090315
13
Clinical recommendations for diagnosis and management of Mendelian susceptibility to mycobacterial disease in resource-limited settings.
Cornelissen H, Glanzmann B, van Coller A, et al.
The journal of allergy and clinical immunology. Global 2025; (4(4)):100540 doi:10.1016/j.jacig.2025.100540.
PMID: 41048447
14
Clinical and genetic features of IL12Rb1 deficiency: Single center experience of 18 patients.
Tan Ç, Çağdaş-Ayvaz D, Metin A, et al.
The Turkish journal of pediatrics 2016; (58(4)):356-361 doi:10.24953/turkjped.2016.04.002.
PMID: 28276206
15
Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children.
Alsuhaibani M, Felimban G, Shoukri M, et al.
International journal of pediatrics & adolescent medicine 2019; (6(2)):47-50 doi:10.1016/j.ijpam.2019.01.003.
PMID: 31388545
16
Measurement and Estimation of Glomerular Filtration Rate in Children.
Mian AN, Schwartz GJ
Advances in chronic kidney disease 2017; (24(6)):348-356 doi:10.1053/j.ackd.2017.09.011.
PMID: 29229165
17
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Nahid P, Dorman SE, Alipanah N, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (63(7)):853-67 doi:10.1093/cid/ciw566.
PMID: 27621353
18
Novel indications for hematopoietic stem cell transplantation in inborn errors of immunity.
Laberko A, Gennery AR
Expert review of clinical immunology 2026; (22(2)):183-193 doi:10.1080/1744666X.2026.2641540.
PMID: 41786511
19
Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical, Immunological, and Genetic Features of 22 Patients from 15 Moroccan Kindreds.
Errami A, Baghdadi JE, Ailal F, et al.
Journal of clinical immunology 2023; (43(4)):728-740 doi:10.1007/s10875-022-01419-x.
PMID: 36630059

This page is for informational purposes only and does not constitute medical advice. Treatment decisions for a child with complete RORC deficiency must be individualized by the child’s immunology and infectious disease team.

Guide Contents